30. Reyvow

Eli Lilly
(Eli Lilly)

Active ingredient: lasmiditan
Disease: migraine
Peak sales estimate: ~$500 million
Approved: Oct. 11, 2019
Company: Eli Lilly

The scoop: Eli Lilly is already working to grow market share for its migraine prevention drug Emgality, but now the company has a new medicine to add to its suite. Reyvow, a first-in-class drug Lilly picked up with its 2017 CoLucid buyout, won approval in the fall to treat migraines as they occur. Reyvow will be the latest launch for the company's growing pain and migraine franchise, but analysts at SVB Leerink said its label and side effects will prevent it from being a “significant” drug revenue-wise. Instead, it will become a niche medicine with under $500 million in peak sales. — Ben Adams

30. Reyvow

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.